Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all ‘non-adverse’ risk AML

Ladha, Abdullah; Hui, Gavin; Cheung, Edna; Berubé, Caroline; Coutre, Steven; Gotlib, Jason; Liedtke, Michaela; Zhang, Tian Yi; Muffly, Lori; Mannis, Gabriel N.

doi:10.1080/10428194.2021.1876869

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody drug conjugates (ADC) represent an attractive approach to treat various hematologic malignancies [102]. After successful introduction of brentuximab vedotin for the treatment of Hodgkin lymphomas and T cell lymphomas and significant success of revived gemtuzumab ozogamicin in acute myeloid leukemia, myeloma has gained its desired attention with ADCs too [103,104]. The basic idea of these drugs is to deliver the cytotoxic drug (referred to as a payload) directly to the malignant cells.…”

Section: Antibody Drug Conjugatesmentioning

confidence: 99%

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

Radocha

Donk

Weisel

2021

Cancers

View full text Add to dashboard Cite

Multiple myeloma is the second most common hematologic malignancy. Current treatment strategies are mainly based on immunomodulatory drugs, proteasome inhibitors or combination of both. Novel agents added to these backbone treatments represent a promising strategy in treatment of newly diagnosed as well as relapsed and refractory multiple myeloma patients. In this respect, the incorporation of monoclonal antibodies into standard-of-care regimens markedly improved prognosis of myeloma patients during the last years. More specifically, monoclonal anti-CD38 antibodies, daratumumab and isatuximab, have been implemented into treatment strategies from first-line treatment to refractory disease. In addition, the monoclonal anti-SLAM-F7 antibody elotuzumab in combination with immunomodulatory drugs has improved the clinical outcomes of patients with relapsed/refractory disease. Belantamab mafodotin is the first approved antibody drug conjugate directed against B cell maturation antigen and is currently used as a monotherapy for patients with advanced disease. This review focuses on clinical efficacy and safety of monoclonal antibodies as well as antibody drug conjugates in multiple myeloma.

show abstract

Section: Antibody Drug Conjugatesmentioning

confidence: 99%

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

Radocha

Donk

Weisel

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…The decision to add GO to standard intensive chemotherapy is based on risk stratification as per the ELN genetic risk classification system, where GO has been shown to provide a significant survival benefit in cases of favorable-risk AML, and modest benefit for intermediate-risk [ 51 ]. Incorporating GO into conventional treatment regimens notably resulted in a 5-year OS improvement of 20% in the core binding factor (CBF) subset of favorable-risk AML [ 52 ].…”

Section: Established Biomarkers In Amlmentioning

confidence: 99%

Role of Biomarkers in the Management of Acute Myeloid Leukemia

Small

Platanias

2022

IJMS

View full text Add to dashboard Cite

Despite many recent advances in treatment options, acute myeloid leukemia (AML) still has a high mortality rate. One important issue in optimizing outcomes for AML patients lies in the limited ability to predict response to specific therapies, duration of response, and likelihood of relapse. With evolving genetic characterization and improving molecular definitions, the ability to predict outcomes and long-term prognosis is slowly improving. The majority of the currently used prognostic assessments relate to molecular and chromosomal abnormalities, as well as response to initial therapy. These risk categories, however, do not account for a large amount of the variability in AML. Laboratory techniques now utilized in the clinic extend beyond bone marrow morphology and single gene sequencing, to next-generation sequencing of large gene panels and multiparameter flow cytometry, among others. Other technologic advances, such as gene expression analysis, have yet to demonstrate enough predictive and prognostic power to be employed in clinical medicine outside of clinical trials, but may be incorporated into the clinic in the future. In this review, we discuss the utility of current biomarkers, and present novel biomarker techniques and strategies that are in development for AML patients. Measurable residual disease (MRD) is a powerful prognostic tool that is increasingly being incorporated into clinical practice, and there are some exciting emerging biomarker technologies that have the potential to improve prognostic power in AML. As AML continues to be a difficult-to-treat disease with poor outcomes in many subtypes, advances in biomarkers that lead to better treatment decisions are greatly needed.

show abstract

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes

Loschi

Fenaux

Cluzeau

2022

Cancers

View full text Add to dashboard Cite

TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are among the myeloid malignancies with the poorest prognosis. In this review, we analyze the prognosis of these two diseases, focussing particularly on the extent of the mono or biallelic mutation status of TP53 mutation, which is largely correlated with cytogenetic complexity. We discuss the possible/potential improvement in outcome based on recent results obtained with new drugs (especially eprenetapopt and magrolimab). We also focus on the impact of allogeneic hematopoietic stem cell transplantation (aHSCT) including post aHSCT treatment.

show abstract

Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all ‘non-adverse’ risk AML

Cited by 3 publications

References 11 publications

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

Role of Biomarkers in the Management of Acute Myeloid Leukemia

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes

Contact Info

Product

Resources

About